Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.

Affiliation

From the Departments of Radiology (J.M.H.) and Clinical Pharmacy (K.V.N.), University of Colorado Hospital, Aurora; Department of Neurology (K.V.N., S.S., B.V., E.A., T.S., J.R.C., T.L.V.), University of Colorado, and Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora; and Department of Neurology (A.M.), University of Florida, Gainesville. Dr. Miravalle is currently at Advanced Neurology of Colorado, Fort Collins, Colorado. [Email]

Abstract

To examine whether rituximab induction followed by glatiramer acetate (GA) monotherapy is more effective than GA alone for the treatment of relapsing multiple sclerosis with active disease.